UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000439
Receipt number R000000533
Scientific Title Phase 1/2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer
Date of disclosure of the study information 2006/07/01
Last modified on 2010/11/04 10:11:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase 1/2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer

Acronym

Phase1/2 study of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer

Scientific Title

Phase 1/2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer

Scientific Title:Acronym

Phase1/2 study of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer

Region

Japan


Condition

Condition

Preaviously untreated advanced advanced squamous cell lung cancer

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of gemcitabine and nedaplatin in patients with previously untreated squamous cell lung cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase I,II


Assessment

Primary outcomes

Recommended dose
Dose limmiting toxicity
Response Rate

Key secondary outcomes

Overall survival
Time to progression
Toxicity


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Combination chemotherapy with gemcitabine and nedaplation

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Squamous cell lung cancer
2) Measurable lesions
3) Preaviously untreated advanced squamous cell lung cancer
4) PS(ECOG)0-1
5) Adequate organ fanctions
6) A life expectacy of at least 3 months
7) Written informed consent

Key exclusion criteria

1) Interstitial pneumonia or pulmonary fibrosis on chest X-P
2) peural or pericardial effusion requiring drainage
3) SVC syndrome
4) Symptomatic brain metastases
5) Active concominant malignancies
6) Uncontrolled diabetes mellitus or hypertension
7) Liver cirrhosis
8) Severe cardiovascular diseases
9) Pregnancy and lactation
10) Ccr<60ml/min
11) A history of serious drug allergy
12) Acute infection
13) Bleeding tendency
14) Unsuitable for entry to the study, decided by a medical oncologist

Target sample size

32


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tadashi Mio(Head),Katsuhiro Masago(Secretariat)

Organization

Kyoto University Hospital

Division name

Department of Respiratory Medicine

Zip code


Address

54 Syogoin, Kawaramachi,Sakyo-Ku,Kyoto-City, Kyoto,Japan

TEL

075-751-3830

Email



Public contact

Name of contact person

1st name
Middle name
Last name Katsuhiro Masago

Organization

Kyoto unversity hospital

Division name

Department of Respiratory Medicine

Zip code


Address

54 Syogoin, Kawaramachi,Sakyo-Ku,Kyoto-City, Kyoto,Japan

TEL

075-751-3830

Homepage URL


Email

mio@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Department of Respiratory Medicine of Kyoto University Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

京都大学医学部付属病院


Other administrative information

Date of disclosure of the study information

2006 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2006 Year 05 Month 08 Day

Date of IRB


Anticipated trial start date

2006 Year 07 Month 01 Day

Last follow-up date

2009 Year 07 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2006 Year 06 Month 28 Day

Last modified on

2010 Year 11 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000533


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name